







## **Open PHACTS**

### Milestone 6

Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented

#### Also covers:

D 3.2.5 Open PHACTS Discovery Platform version 3.0 developed and 'signed off' by TTF and EC on criteria formulated in WP1-6

D 4.5.5 Final version of LDC and services as sustainable production type

Prepared by Lee Harland (SciBite), Anika Robl (UNIVIE) Approved by SciBite, UNIVIE, CD, Pfizer, VUA, GSK, NBIC

> August 2014 Version 1.0

An open, integrated and sustainable chemistry, biology and pharmacology Project title:

knowledge resource for drug discovery

Instrument: IMI JU Contract no: 115191

Start date: 01 March 2011 Duration: 60 months

Nature of the Deliverable		
Report		
Prototype	X	
Other		
Dissemination level		
Public dissemination level		
For internal use only		

Open PHACTS	Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented	Milestone D 3.2.5 & 4	
IMI - 115191	Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)	Version: 1.0	2/8

### **Definitions**

Partners of the Open PHACTS Consortium are referred to herein according to the following codes:

- 1 GSK GlaxoSmithKline Coordinator
- 2 UNIVIE Universität Wien Managing Entity of IMI JU funding
- 3 DTU Technical University of Denmark
- 4 UHAM University of Hamburg, Center for Bioinformatics
- 5 BIT BioSolveIT GmbH
- 6 PSMAR Consorci Mar Parc de Salut de Barcelona
- 601 FIMIM Fundacio Institut Mar d'Investigacions Mediques
- 602 UPF Universitat Pompeu Fabra
- 7 LUMC Leiden University Medical Centre
- 8 RSC Royal Society of Chemistry
- 801 RSCWW RSC World Wide Ltd
- 9 VUA Stichting VU-VUMC
- 10 CNIO Centro Nacional de Investigaciones Oncológicas
- 11 UNIMAN University of Manchester
- 12 UM Universiteit Maastricht
- **13 ACK** ACKnowledge
- 14 USC Universidade de Santiago de Compostela
- 15 UBO Rheinische Friedrich-Wilhelms-Universität Bonn
- 16 AZ AstraZeneca AB
- 17 Pfizer Pfizer Limited
- 18 Esteve Laboratorios del Dr. Esteve, S.A.
- 19 Novartis Novartis Pharma AG
- **20 ME** Merck
- 21 HLU H. Lundbeck A/S
- 22 Lilly Eli Lilly and Company Limited
- 23 NBIC Stichting Netherlands Bioinformatics Centre
- 24 SIB Swiss Institute of Bioinformatics
- **25 CD** Connected Discovery
- **26 EMBL-EBI** European Molecular Biology Laboratory
- 27 Janssen Janssen Pharmaceutica NV
- 28 OGL OpenLink Group Ltd
- 29 OPF The Open PHACTS Foundation
- 30 ALM Laboratorios Almirall S.A.
- 31 SciBite SciBite Limited

Open PHACTS	Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented	Mileston D 3.2.5 & 4	
IMI - 115191	Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)	Version: 1.0	3/8

### 1 Introduction

This Milestone 6 also covers the following deliverables:

- **D 3.2.5** Open PHACTS Discovery Platform version 3.0 developed and 'signed off' by TTF and EC on criteria formulated in WP1-6 (Prototype)
- **D 4.5.5** Final version of LDC and services as sustainable production type (Prototype)

### 2 Open PHACTS Discovery Platform hosted and running

A key goal for the project is to host the Open PHACTS Discovery Platform on a professional hosting environment. The first phase of this work was the recruitment of the hosting partner through a competitive tender process. The successful applicant was OpenLink, and work was then undertaken to install the system on their servers. This was a considerable undertaking, and required:

- Purchase and configuration of the correct hardware
- Packing and testing of Open PHACTS software and data for transition to OpenLink
- Install of the core platform on the OpenLink servers
- Connection of the hosted core to the additional Open PHACTS services (ConceptWiki, IMS, ChemSpider)
- Installation of the GUI (Explorer) on the OpenLink servers
- Configuration of access, security (SSL certificates)
- Use of 3 scale as an API provider, providing extensive management and tracking capabilities
- Installation and configuration of logging and system monitoring (see D 4.6.3)

This complex procedure was carried out jointly by the core platform developers and OpenLink and required many hours of testing and validation. However, due to the design principles behind the system, the installation proceeded in good time and resulted in a fully working on the OpenLink servers.

The Open PHACTS Discovery Platform is now running 24/7 and is used by Academia as well as EFPIA. As shown in Appendix 1, the Open PHACTS API is gaining significant usage from a wide variety of organisations. The appendix shows a weekly usage report from three selected weeks – demonstrating that while the "top users" each week will obviously vary, there is a good mix of different organisations, including pharma and academia.

The Open PHACTS Explorer is running on the OpenLink server at <u>explorer.openphacts.org</u> and the Open PHACTS API at <u>dev.openphacts.org</u>. Feedback from users is gathered via the support portal available at <u>support.openphacts.org</u> (tickets and forum) or alternatively via email to <u>support@openphacts.org</u>.

Open PHACTS	Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented	Milestone D 3.2.5 & 4	
IMI - 115191	Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)	Version: 1.0	4/8

### **Related publications:**

Paul Groth, Antonis Loizou, Alasdair J.G. Gray, Carole Goble, Lee Harland, Steve Pettifer, API-centric Linked Data integration: The Open PHACTS Discovery Platform case study, Web Semantics: Science, Services and Agents on the World Wide Web, Available online 8 April 2014, ISSN 1570-8268

http://dx.doi.org/10.1016/j.websem.2014.03.003.

Special Issue: Open Innovation in Drug Discovery. Molecular Informatics, Volume 31, Issue 8, 517-609, August 2012

http://onlinelibrary.wiley.com/doi/10.1002/minf.v31.8/issuetoc

Gray AJ, Groth P, Loizou A, Askjaer S, Brenninkmeijer C, Burger K, Chichester C, Evelo CT, Goble C, Harland L, Pettifer S, Thompson M, Waagmeester A, Williams AJ (2012) Applying Linked Data Approaches to Pharmacology: Architectural Decisions and Implementation. Semantic Web Journal.

http://www.semantic-web-journal.net/content/applying-linked-data-approaches-pharmacology-architectural-decisions-and-implementation

Williams AJ, Harland L, Groth P, Pettifer S, Chichester C, Willighagen EL, Evelo CT, Blomberg N, Ecker GF, Goble C, Mons B (2012) Open PHACTS: semantic interoperability for drug discovery. Drug Discovery Today, Volume 17, Issues 21-22, 1188-1198. http://www.sciencedirect.com/science/article/pii/S1359644612001936

Further publications can be found on our website: <a href="http://www.openphacts.org/news-and-events/publications">http://www.openphacts.org/news-and-events/publications</a>

# 3 Long term funding implemented with permanent beta developer team

A major milestone towards sustainability has been reached in August 2013, when the Open PHACTS Foundation, a not-for-profit membership organisation, was established. The aim of the Open PHACTS Foundation is to start to build a membership to continue the work of the project, ensuring the infrastructure is sustained and extended, and the needs of the scientific community served. In December 2013, the Open PHACTS Foundation joined the Open PHACTS project as a partner.

In June 2014, the Open PHACTS Foundation proudly announced its first three members – GlaxoSmithKline, Janssen and Roche – who will steer the future of the successor organisation to the Open PHACTS project. The commitment by these global pharmaceutical industry members signifies a major step in ensuring the sustainability of infrastructure developed during the Open PHACTS project. The Open PHACTS community covering academia, industry, application developers and semantic web experts has delivered a

Open PHACTS	Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented	Milestone D 3.2.5 & 4	
IMI - 115191	Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)	Version: 1.0	5/8

powerful cloud-based data platform, demonstrating the effectiveness of robust data integration in answering real scientific questions.

As a leading IMI project, the Open PHACTS project has built a sustainable succession plan through the Foundation to both continue provision of the Open PHACTS Discovery Platform and to extend the coverage of data and functionality. Collaboration with existing and future consortia will engage the scientific community and involve relevant applied life science R&D.

A core developer team is now responsible for maintaining and enhancing the Open PHACTS API. This core group consists of staff from the RSC, VU, UNIMAN and SIB. Routine teleconferences and skype discussions are held and the git system is used to provide extensive issue tracking and discussion (see appendix 2). As outlined in D 3.2.6 (A full technical sustainability plan delivered and signed off by TTF and EC to continue Open PHACTS beyond the duration of the Open PHACTS project and consortium), the Open PHACTS Foundation has successfully signed a contract with UNIMAN to provide technical resource for maintaining the platform. This represents a major step forward in the long term stability of the system.

### 4 Secure access implemented

The Open PHACTS API is accessible via <u>dev.openphacts.org</u>, which is secured with an SSL certificate. The system is now fully secured and private in accordance with a detailed specification worked out between the Open PHACTS team, Open Link and EFPIA. The full document is available at <a href="http://www.openphactsfoundation.org/security">http://www.openphactsfoundation.org/security</a>.

Open PHACTS	Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented	Milestone 6 D 3.2.5 & 4.5.5
IMI - 115191	Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)	Version: 1.0 6 / 8

### Appendix 1: Selection of usage reports



2014-08-31 - 2014-08-25

# Weekly Report (dev.openphacts.org - API) Traffic



Top Users: University (202978 hits), University (152650), Explorer (39333), SME (34390), Pharma (24268)



2014-05-14 - 2014-05-08

### Weekly Report (dev.openphacts.org)

Traffic



Top Users: University (81284 hits), Explorer (54638), Pharma (40786), Pharma (24256), Pharma (16456)



2014-08-21 - 2014-08-15

### Weekly Report (dev.openphacts.org - API)


Traffic



Top Users: Pharma (90121 hits), Commercial Organisation (61236), Explorer (30808), Pharma (24212), University (24146)

Open PHACTS	Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented	Milestone D 3.2.5 & 4	
IMI - 115191	Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)	Version: 1.0	7/8

### **Appendix 2: Git Hub for Core Developers**



Open
PHACTS

Milestone: Long term funding implemented with permanent beta developer team; Open PHACTS Discovery Platform hosted and running; secure access implemented

Milestone 6 D 3.2.5 & 4.5.5

IMI - 115191

Authors: Lee Harland (SciBite), Anika Robl (UNIVIE)

Version: 1.0 8 / 8

